IBI Ag Secures $6.1 Million in Funding Round Led by Corteva Inc.

Rhea-AI Summary

IBI Ag has secured $6.1 million in the first tranche of its Series A funding round, led by Corteva through its Corteva Catalyst platform. Other participants include The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, along with a grant from the Israel Innovation Authority.

The company is developing bio-insecticides using single domain antibody technology, adapted from pharmaceutical applications for agricultural use. Their products target both sucking and chewing insects while maintaining a low ecological footprint and minimal impact on non-targeted organisms. The technology focuses initially on high-value crops with plans to expand to row crop solutions.

Positive

• Secured $6.1M in Series A funding led by major agricultural company Corteva
• Technology targets broad spectrum of insects with minimal environmental impact
• Strategic partnership with Corteva provides validation of technology platform
• Additional funding through Israel Innovation Authority grant

Negative

• Products still under development, not yet commercialized
• Initial focus to high-value crops only

This is the first tranche of a Series A Round for IBI Ag's novel bioinsecticide platform.

NES TZIONA, Israel, Feb. 13, 2025 /PRNewswire/ -- IBI Ag, a pioneering crop protection company developing a wide array of bio-insecticides with a lower ecological footprint, today announced it has successfully closed the first part of its Series A funding round with a $6.1 million investment. This round—led by Corteva, Inc. ("Corteva"), through its Corteva Catalyst platform with the participation of The Trendlines Group (SGX:42T) (OTCQX:TRNLY), Iron Nation, Consensus Business Group ("CBG") and a grant from the Israel Innovation Authority —underscores the strategic importance of IBI Ag's innovative biological and naturally-inspired solutions in the global agricultural sector to assist farmers in producing more food by protecting their crops and the global food chain.

IBI Ag has developed technology that leverages single domain antibodies, to produce highly effective crop protection solutions with a low ecological footprint. This technology—adapted from pharma and modified to fit the agricultural market—provides novel modes of action and represents a revolutionary new approach for protecting crops from insects. The products under development target a broad spectrum of insects, both sucking and chewing insects with minimal impact on non-targeted organisms. The company is targeting high value crops to start and will follow with row crop solutions.

"We are thrilled to have the support of our existing and new investors, led by Corteva through their Corteva Catalyst platform," said Arnon Heyman, Chief Executive Officer, IBI Ag. "This investment will help us to accelerate the development of our single domain antibody technology, providing farmers with sustainable and effective crop protection solutions. We believe our single domain antibody technology is a game changer for driving agricultural productivity while preserving the environment, and the investment announced today is a significant step towards delivering this innovation to farmers across the globe."

"We see considerable potential for IBI Ag's bioinsecticides to be a smart solution for farmers to tackle devastating insects while minimizing environmental impacts," said Tom Greene, Senior Director at Corteva Inc. and Global Leader for Corteva Catalyst. "Our investment aligns with our continued drive to put cutting-edge innovation into the hands of farmers and reflects our strategic focus on accelerating development of next generation biological and naturally inspired solutions."

About IBI Ag
IBI-Ag is a pioneer in the Agri-biotech industry, committed to developing innovative and sustainable solutions for crop protection. The company's proprietary technology platform, the first of its kind, utilizes nano-bodies—a type of antibody—to create effective, selective, and safe biological insect control solutions. This breakthrough technology has the potential to protect the global food chain by helping farmers protect their crops with a lower ecological footprint and to transform the agricultural industry by offering an environmentally friendly and cost-effective alternative to chemical pesticides. IBI Ag was established by The Trendlines Group together with the founders Amir Ayali PhD and Rony Oren Benaroya PhD, and with the support of the Israel Innovation Authority.

Media Contacts:
IBI Ag: Arnon Heyman, CEO IBI Ag, e-mail: Arnon.heyman@ibi-ag.com

Photo - https://mma.prnewswire.com/media/2619674/IBI_Ag_team.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ibi-ag-secures-6-1-million-in-funding-round-led-by-corteva-inc-302375928.html

SOURCE IBI Ag

FAQ

How much funding did IBI Ag raise in its Series A round first tranche?

IBI Ag raised $6.1 million in the first tranche of its Series A funding round.

Who led IBI Ag's Series A funding round in February 2025?

Corteva led the funding round through its Corteva Catalyst platform.

What is unique about IBI Ag's bioinsecticide technology?

IBI Ag's technology uses single domain antibodies adapted from pharma applications, providing novel modes of action for crop protection with minimal impact on non-targeted organisms.

Which markets will IBI Ag's bioinsecticide products initially target?

The products will initially target high-value crops before expanding to row crop solutions.

What role does Trendlines Group (TRNLY) play in IBI Ag's funding round?

The Trendlines Group (TRNLY) participated as one of the investors in the $6.1 million Series A funding round.